Figure 6.

Medrysone treatment accompanies PLP recovery and remyelination-related astrogliosis at the corpus callosum adjacent to the dorsal SVZ. (a-d) Representative pictures showing PLP expression at the a-CC. (e) Quantification of PLP fluorescence intensity units revealed a demyelination induced decrease of PLP expression and a medrysone enhanced recovery of PLP levels. Representative photomicrographs of active myelinating OLs at the a-CC (Sox10+/Bcas1+). Quantification of active myelinating OLs at the a-CC (j) revealed a decrease of these cells during demyelination and medrysone to strongly counteract this effect. (k-n) Representative photomicrographs of DRAs (Lcn2+/iNOS+/GFP+) at the a-CC. (o) Quantification of DRA shows enhancement of this phenotype over demyelination and saline 1 WPC. (p-s) Representative photomicrographs of RRAs (C3d+/Timp1+/GFP+). (t) Quantification of RRA revealed that medrysone increased this phenotype at the early recovery phase. Abbreviations: Lateral ventricle (LV), demyelination related astrocytes (DRA), remyelination related astrocytes (RRA). Bars (e) correspond to PLP mean signal fluorescence intensity ± standard error of the mean (SEM), bars in (g, o, t) correspond to mean cell numbers per mm² ± standard error of the mean (SEM). Statistical significance was calculated using a two-way ANOVA with multiple comparisons Bonferroni post-test (*p < 0.05, **p < 0.01, and ***p < 0.001). Number of animals n=5 (e, j, o), n=4 (t). Exact p-values according to sequence from left to right: e: (p=0.000006352482916, p=0.000002232001001, p=0.002400718707233, p=0.000115165255505, p=0.002114723859805, p=0.000711683124652, p=0.000036763007099, p=0.00062825077472). j: (p=0.003491161340599, p=0.003020739853541, p=0.000026903857775, p=0.000581789413022, p=0.03812643142709). o: (p=0.000012264417485, p=0.000006109495876, p=0.00006100471827, p=0.000023087347467, p=0.000008980415351, p=0.000029360883258, p=0.000011341827324, p=0.000004504968109). t: (p=0.006949092405986, p=0.006949092405986).